A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A

Conditions

• Hemophilia A

Interventions

• DRUG: Recombinant human activated coagulation factor VIII for injection

Sponsor

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.